Showing results (2201-2210 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|February 1, 1993
Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancerG T Budd, R M Bukowski, A Lichtin, et al.Investigational New Drugs|July 21, 2021
Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studiesGeriletu Ao, Maria de Miguel, Ana Gomes, et al.Investigational New Drugs|January 1, 1983
Activity of two phase I drugs N-methylformamide (NSC-3051) and Echinomycin (NSC-526417) against fresh surgical explants of human tumors in the 6-day subrenal capsule (SRC) assayW R Cobb, A E Bogden, S D Reich, et al.Investigational New Drugs|January 1, 1983
Anaphylactoid reactions associated with bisantrene infusionsJ W Myers, D D Von Hoff, J G Kuhn, et al.Investigational New Drugs|January 1, 1983
Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugsS C Barranco, C M Townsend, M A Quraishi, et al.Investigational New Drugs|January 1, 1983
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluentsR T Dorr, D S AlbertsInvestigational New Drugs|January 1, 1983
The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activityB Drewinko, L Y YangInvestigational New Drugs|January 1, 1983
Effect of 2,3-dihydro-1H-imidazo [1,2-b]pyrazole (IMPY) on the metabolism of human red cellsA L Sagone, J A Neidhart, R M HusneyInvestigational New Drugs|January 1, 1983
Characterization of the pharmacokinetics of bisantrene (NSC-337766)J G Kuhn, T M Ludden, J W Myers, et al.Investigational New Drugs|January 1, 1983
Human muscle: a model for the study of human neoplasiaJ C Petricciani, I Levenbook, R LockePageof 372